NAUT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.140

-0%

-0.165

+26.92%

-0.150

+25%

Estimates Revision

The market is revising No Change the revenue expectations for Nautilus Biotechnology, Inc. (NAUT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 128.89%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.89%

In Past 3 Month

Stock Price

Go Up

+128.89%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

No data

Valuation Metrics

The current forward P/E ratio for Nautilus Biotechnology Inc (NAUT.O) is -3.16, compared to its 5-year average forward P/E of -6.57. For a more detailed relative valuation and DCF analysis to assess Nautilus Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.57

Current PE

-3.16

Overvalued PE

0.33

Undervalued PE

-13.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.65

Current EV/EBITDA

-1.86

Overvalued EV/EBITDA

1.26

Undervalued EV/EBITDA

-6.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

527.65

Current PS

0.00

Overvalued PS

1667.21

Undervalued PS

-611.91

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 499900% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NAUT News & Events

Events Timeline

No data

News

9.5

2025-10-28NASDAQ.COM

Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary

9.0

2025-10-23NASDAQ.COM

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

5.0

2025-09-11NASDAQ.COM

Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth

People Also Watch

Frequently Asked Questions

What is Nautilus Biotechnology Inc (NAUT) stock price today?

The current price of NAUT is 2.06 USD — it has decreased -7.21 % in the last trading day.

What is Nautilus Biotechnology Inc (NAUT)'s business?

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

What is the price predicton of NAUT Stock?

What is Nautilus Biotechnology Inc (NAUT)'s revenue for the last quarter?

Nautilus Biotechnology Inc revenue for the last quarter amounts to -15.47M USD, decreased -18.99 % YoY.

What is Nautilus Biotechnology Inc (NAUT)'s earnings per share (EPS) for the last quarter?

Nautilus Biotechnology Inc. EPS for the last quarter amounts to -11452000.00 USD, decreased -17.15 % YoY.

What changes have occurred in the market's expectations for Nautilus Biotechnology Inc (NAUT)'s fundamentals?

How many employees does Nautilus Biotechnology Inc (NAUT). have?

Nautilus Biotechnology Inc (NAUT) has 155 emplpoyees as of January 10 2026.

What is Nautilus Biotechnology Inc (NAUT) market cap?

Today NAUT has the market capitalization of 260.19M USD.